12/4
07:00 am
catx
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
High
Report
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
11/24
11:00 am
catx
Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Low
Report
Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
11/24
08:08 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.
Neutral
Report
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.
11/24
08:06 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.
Neutral
Report
Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.
11/20
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming December Conferences
Medium
Report
Perspective Therapeutics to Participate in Upcoming December Conferences
11/10
04:05 pm
catx
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
Low
Report
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results
10/31
07:00 am
catx
Perspective Therapeutics to Participate in Upcoming November Conferences
Low
Report
Perspective Therapeutics to Participate in Upcoming November Conferences
10/24
07:00 am
catx
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
Low
Report
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results
10/20
04:00 am
catx
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025
High
Report
Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025
10/3
08:08 am
catx
Perspective Therapeutics (NYSE:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Perspective Therapeutics (NYSE:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/2
10:29 am
catx
Perspective Therapeutics (NYSE:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Perspective Therapeutics (NYSE:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
10/2
07:00 am
catx
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors
Low
Report
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-a Positive Solid Tumors
9/19
08:07 am
catx
Perspective Therapeutics (NYSE:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Perspective Therapeutics (NYSE:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/15
11:03 pm
catx
Perspective Therapeutics (NYSE:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Perspective Therapeutics (NYSE:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
9/15
07:00 am
catx
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Low
Report
Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma